
Bausch Health Companies BHC
€ 6.08
-0.56%
Quartalsbericht 2024-Q2
hinzugefügt 01.08.2024
Bausch Health Companies Betriebsaufwand 2011-2025 | BHC
Betriebsaufwand Jährlich Bausch Health Companies
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 4.96 B | 5.53 B | 5.64 B | 5.96 B | 5.71 B | 3.55 B | 3.6 B | 1.82 B | 1.31 B |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 5.96 B | 1.31 B | 4.23 B |
Betriebsaufwand anderer Aktien in der Arzneimittelhersteller
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
71.8 M | - | - | $ 142 M | ||
|
Aerie Pharmaceuticals
AERI
|
213 M | - | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
197 M | $ 1.21 | 1.68 % | $ 130 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
40.3 M | - | 7.5 % | $ 6.35 M | ||
|
Cronos Group
CRON
|
154 M | $ 2.67 | 0.19 % | $ 1.39 B | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
38.9 M | - | 0.86 % | $ 117 M | ||
|
Catalent
CTLT
|
512 M | - | - | $ 11.5 B | ||
|
Agile Therapeutics
AGRX
|
30.5 M | - | 10.11 % | $ 58.2 M | ||
|
DURECT Corporation
DRRX
|
44.6 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
113 M | - | -39.89 % | $ 27.7 M | ||
|
Aurora Cannabis
ACB
|
183 M | $ 4.35 | -3.12 % | $ 86.3 M | ||
|
Endo International plc
ENDP
|
763 M | - | - | $ 28.9 M | ||
|
Zomedica Corp.
ZOM
|
14.1 M | - | -0.21 % | $ 98 M | ||
|
Evoke Pharma
EVOK
|
12.6 M | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
213 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
106 M | - | 2.45 % | $ 38.1 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
35.3 M | - | - | $ 55.5 M | ||
|
Emergent BioSolutions
EBS
|
558 M | $ 12.29 | -1.09 % | $ 629 M | ||
|
Athenex
ATNX
|
96.7 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
196 M | $ 21.57 | -0.12 % | $ 2.05 B | ||
|
Evolus
EOLS
|
107 M | $ 6.66 | -3.55 % | $ 413 M | ||
|
Harrow Health
HROW
|
90.1 M | $ 50.7 | 1.22 % | $ 1.65 B | ||
|
China Pharma Holdings
CPHI
|
2.6 M | $ 1.27 | -1.32 % | $ 22.2 M | ||
|
OrganiGram Holdings
OGI
|
41.4 M | $ 1.7 | -5.31 % | $ 402 M | ||
|
Neoleukin Therapeutics
NLTX
|
55.6 M | - | - | $ 193 M | ||
|
Organogenesis Holdings
ORGO
|
368 M | $ 5.19 | -1.71 % | $ 683 M | ||
|
Lannett Company
LCI
|
209 M | - | 1.15 % | $ 7.11 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
9.18 M | $ 3.66 | 0.83 % | $ 4.54 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
35.2 M | $ 4.01 | -2.55 % | $ 56.4 M | ||
|
Rockwell Medical
RMTI
|
31.1 M | $ 0.8 | -7.01 % | $ 18.7 M | ||
|
Pacira BioSciences
PCRX
|
279 M | $ 26.17 | -1.3 % | $ 1.21 B | ||
|
Sundial Growers
SNDL
|
102 K | $ 1.71 | -1.16 % | $ 3.37 M | ||
|
PetIQ
PETQ
|
138 M | - | 1.64 % | $ 400 M | ||
|
Jupiter Wellness
JUPW
|
39.6 M | - | - | $ 33.6 M | ||
|
Veru
VERU
|
44 M | $ 2.22 | -7.71 % | $ 299 M | ||
|
Perrigo Company plc
PRGO
|
1.43 B | $ 13.94 | 0.87 % | $ 1.92 B | ||
|
ProPhase Labs
PRPH
|
47.1 M | $ 0.45 | -14.17 % | $ 7.13 M | ||
|
Radius Health
RDUS
|
304 M | - | - | $ 1.42 B | ||
|
cbdMD
YCBD
|
28.9 M | $ 1.43 | -15.88 % | $ 6.17 M | ||
|
Recro Pharma
REPH
|
22.5 M | - | -4.76 % | $ 65.3 M | ||
|
Relmada Therapeutics
RLMD
|
104 M | $ 4.43 | -1.77 % | $ 133 M | ||
|
OptiNose
OPTN
|
129 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
133 M | $ 9.56 | -3.82 % | $ 679 M | ||
|
PLx Pharma
PLXP
|
44.2 M | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
130 M | $ 5.63 | -3.68 % | $ 230 M | ||
|
SCYNEXIS
SCYX
|
67.5 M | $ 0.63 | 6.75 % | $ 30.1 M | ||
|
Tricida
TCDA
|
153 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
1.52 B | $ 9.32 | -2.87 % | $ 5.76 B | ||
|
TherapeuticsMD
TXMD
|
9.82 M | $ 1.68 | -3.43 % | $ 17.5 M |